Clinical Trial Update: Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating neoadjuvant therapy with gemcitabine, nab-paclitaxel, durvalumab, and oleclumab for resectable or borderline resectable pan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer
• Pancreatic Cancer
• Resectable Pancreatic Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Oleclumab (oleclumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING